Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 7/2012

01-07-2012 | Technical Innovation

Sleeve Gastrectomy with Jejunal Bypass for the Treatment of Type 2 Diabetes Mellitus in Patients with Body Mass Index <35 kg/m2. A cohort study

Authors: Munir Alamo, Matías Sepúlveda, José Gellona, Mauricio Herrera, Cristián Astorga, Carlos Manterola

Published in: Obesity Surgery | Issue 7/2012

Login to get access

Abstract

The objective of this study was to evaluate sleeve gastrectomy with jejunal bypass (SGJB) as a surgical treatment for type 2 diabetes mellitus (T2DM) in patients with a body mass index (BMI) <35 kg/m2. This is a prospective cohort study. Patients with T2DM and BMI <35 kg/m2 who underwent SGJB between January 2009 and June 2011 at DIPRECA Hospital, in Santiago, and Hospital Base, Osorno, Chile were included. SGJB consists of creating a gastric tube, which preserves the pylorus, and performing a jejunoileal anastomosis 300 cm distal to the angle of Treitz. Excess weight loss (EWL) and complete or partial remission of T2DM were reported. Forty-nine patients met the inclusion criteria. The mean age was 49 years (36–62), and 53 % of patients were female. Mean preoperative BMI was 31.6 kg/m2 (25–34.9 kg/m2). Operation time was 123 ± 14 min, with 94.7 % of operations performed laparoscopically. Mean postoperative hospital stay was 2 days. Mean postoperative follow-up was 12 months. Median EWL at 1, 3, 6, 12, and 18 months postoperatively was 31.9 %, 56.9 %, 76.1 %, 81.5 %, and 76.1 %, respectively. Complete T2DM remission was achieved in 81.6 % of patients (40/49) and partial remission in 18.4 % (9/49). Forty of 41 patients (97.6 %) on oral hypoglycemic agents achieved complete T2DM remission, and 100 % of insulin-dependent patients stopped using insulin but were still being treated for T2DM. One patient experienced postoperative gastrointestinal bleeding. There were no deaths. SGJB is an effective treatment for T2DM in patients with BMI <35 kg/m2.
Literature
1.
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–52.PubMedCrossRef
2.
MacDonald Jr KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1(3):213–20 (discussion: 220).PubMedCrossRef
3.
Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes—a systematic review. Diabetes Metab Res Rev. 2004;20:438–45.PubMedCrossRef
4.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.e5.PubMedCrossRef
5.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
6.
Padwal RS. Review: bariatric surgery reduces weight and improves type 2 diabetes in adults. Evid Based Med. 2009;14(5):138.PubMedCrossRef
7.
Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg. 2010;20:776–90.PubMedCrossRef
8.
Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.PubMedCrossRef
9.
DePaula A, Stival A, Halpern A, et al. Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients. Obes Surg. 2011;21(5):668–75.PubMedCrossRef
10.
Alamo M, Sepúlveda C, Zapata L. Vertical isolated gastroplasty with gastro-enteral bypass: preliminary results. Obes Surg. 2006;16(3):353–8.CrossRef
11.
de Menezes Ettinger JE, Azaro E, Mello CA, et al. Analysis of the vertical isolated gastroplasty: a new bariatric operation. Obes Surg. 2006;16(9):1261–3; author reply 1263–4.CrossRef
12.
Vandenbroucke JP, von Elm E, Altman DG, et al. STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W163–94.PubMed
13.
14.
American Diabetes Association Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62–9.CrossRef
15.
Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Reviews/commentaries/ADA statements consensus statement. Diabetes Care. 2009;32:2133–5.PubMedCrossRef
16.
Robinson JD, Lupkiewicz SM, Palenik L, et al. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40(6):1016–9.PubMed
17.
Bayliss WM, Starling EH. The mechanism of pancreatic secretion. Proc R Soc Lond Biol. 1902;69:352–3.
18.
Elrick H, Stimmler L, Hlad Jr CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Invest. 1964;24:1076–82.
19.
Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009;49(Suppl 1):S16–29.
20.
La Barre J. Sur les possibilités d'un traitement du diabetes par l'incrétine. Bull Acad R Med Belg. 1932;12:620–34.
21.
Miller LJ, Malagelada JR, Taylor WF, et al. Intestinal control of human postprandial gastric function: the role of components of jejunoileal chyme in regulating gastric secretion and gastric emptying. Gastroenterology. 1981;80:763–9.PubMed
22.
Layer P, Holst JJ, Grandt D, et al. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci. 1995;40:1074–82.PubMedCrossRef
23.
Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19(2):217–29.PubMedCrossRef
24.
Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14 Suppl 1:1–83.PubMed
25.
Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146(2):143–8.PubMedCrossRef
26.
Nocca D, Guillaume F, Noel P, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21(6):738–43.PubMedCrossRef
27.
Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6(6):707–13.PubMedCrossRef
28.
Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenaljejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of two cases. Surg Obes Relat Dis. 2007;3:195–7.PubMedCrossRef
29.
DePaula AL, Macedo AL, Mota BR, et al. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc. 2009;23(6):1313–20.PubMedCrossRef
30.
Tinoco A, El-Kadre L, Aquiar L, et al. Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World J Surg. 2011;35(10):2238–44.PubMedCrossRef
31.
Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1–11.PubMedCrossRef
32.
Rubino F, Forgione A, Cummings D, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.PubMedCrossRef
33.
Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725–32.PubMedCrossRef
34.
Gersin KS, Keller JE, Stefanidis D, et al. Duodenal-jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov. 2007;14:275–8.PubMedCrossRef
35.
Rodriguez-Grunert L, Neto MPG, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal by-pass sleeve. Surg Obes Relat Dis. 2008;4:55–9.PubMedCrossRef
36.
Boza C, Muñoz R, Yung E, et al. Sleeve gastrectomy with ileal transposition (SGIT) induces a significant weight loss and diabetes improvement without exclusion of the proximal intestine. J Gastrointest Surg. 2011;15(6):928–34.PubMedCrossRef
37.
Cable CT, Colbert CY, Showalter T, et al. Prevalence of anemia after Roux-en-Y gastric bypass surgery: what is the right number? Surg Obes Relat Dis. 2011;7(2):134–9.PubMedCrossRef
38.
Simon SR, Zemel R, Betancourt S, et al. Hematologic complications of gastric bypass for morbid obesity. South Med J. 1989;82:1108–10.PubMedCrossRef
39.
Alvarez-Cordero R, Aragon-Viruette E. Post-operative complications in a series of gastric bypass patients. Obes Surg. 1992;2:87–9.PubMedCrossRef
40.
Halverson JD. Micronutrient deficiencies after gastric bypass for morbid obesity. Am Surg. 1986;52:594–8.PubMed
41.
Loss AB, de Souza AA, Pitombo CA, et al. Analysis of the dumping syndrome on morbid obese patients submitted to Roux en Y gastric bypass. Rev Col Bras Cir. 2009;36(5):413–9.PubMedCrossRef
42.
Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–90.PubMedCrossRef
43.
Quigley E, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin N Am. 2010;24:943–59.CrossRef
44.
Greco M, De Micheli E, Lonardo A. Multifactorial hepatopathy in a patient with biliopancreatic diversion. Ann Ital Med Int. 2003;18(2):99–103. Italian.PubMed
45.
Papadia F, Marinari GM, Camerini G, et al. Short-term liver function after biliopancreatic diversion. Obes Surg. 2003;13(5):752–5.PubMedCrossRef
46.
Riordan SM, McIver CJ, Williams R. Liver damage in human small intestinal bacterial overgrowth. Am J Gastroenterol. 1998;93(2):234–7.PubMedCrossRef
47.
Reinshagen K, Zahn K, Buch C, et al. The impact of longitudinal intestinal lengthening and tailoring on liver function in short bowel syndrome. Eur J Pediatr Surg. 2008;18(4):249–53.PubMedCrossRef
48.
Martin GR, Beck PL, Sigalet DL. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol. 2006;12(26):4117–29.PubMed
49.
Hartmann B, Thulesen J, Hansen BS, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000;47:370–6.PubMedCrossRef
50.
Santoro S, Milleo FQ, Malzoni CE. Enterohormonal changes alter digestive adaptation: five-year results of a surgical proposal to treat obesity and associated diseases. Obes Surg. 2008;18(1):17–26.PubMedCrossRef
Metadata
Title
Sleeve Gastrectomy with Jejunal Bypass for the Treatment of Type 2 Diabetes Mellitus in Patients with Body Mass Index <35 kg/m2. A cohort study
Authors
Munir Alamo
Matías Sepúlveda
José Gellona
Mauricio Herrera
Cristián Astorga
Carlos Manterola
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 7/2012
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-012-0652-x

Other articles of this Issue 7/2012

Obesity Surgery 7/2012 Go to the issue

Clinical Research

Laparoscopic Adjustable Gastric Banding: A 10-Year Single-Centre Experience of 575 Cases with Weight Loss Following Surgery

Clinical Research

Laparoscopic Conversion of Failed Gastric Banding to Roux-en-Y Gastric Bypass. Short-term Follow-up and Technical Considerations

Clinical Research

GLP-1 Response to a Mixed Meal: What Happens 10 Years after Roux-en-Y Gastric Bypass (RYGB)?

Retraction Note

Retraction Note: First Experiences with A Circular Stapled Gastro-Jejunostomy by a New Transorally Introducible Stapler System in Laparoscopic Roux-en-Y Gastric Bypass

Clinical Research

Effect of Bariatric Surgery on Liver Fibrosis

Animal Research

Roux-en-Y Gastric Bypass in Mice—Surgical Technique and Characterisation